by michaelhalassa | Mar 16, 2026 | ADHD medication and psychosis, Algorithmic psychiatry, Chronic stimulant use, Cobenfy, Computational psychiatry, Distributed neural systems, Dopamine and psychosis, Executive Control, Reward-seeking systems, Schizophrenia, Stimulant side effects, Stimulant-induced psychosis
When I wrote about Stephanie earlier this summer, the 58-year-old executive who kept photographing “dimensional breach points” in her neighbors’ basements, I discussed the potential relationship to her long-term use of prescription stimulant...
by michaelhalassa | Jul 16, 2025 | Cobenfy, Algorithmic psychiatry, Computational psychiatry, Distributed neural systems, Dopamine and psychosis, KarXT, Mental health treatment, Michael Halassa, muscarinic antipsychotic, Schizophrenia treatment, Xanomeline
I had the privilege of attending and in part organizing the inaugural Innovation in Psychosis Therapeutics Summit in Boston (June 9-11, 2025). This intimate gathering brought together scientists, clinicians and biotech leaders who share a common goal: to finally push...
by michaelhalassa | May 14, 2025 | Cobenfy, KarXT
What Cobenfy Teaches Us About the Future of Psychiatric Drug Development The approval of Cobenfy (xanomeline-trospium) marks more than just the arrival of a new antipsychotic. It’s a signal—subtle but decisive—that the center of gravity in psychiatry may be shifting....
by michaelhalassa | Mar 11, 2025 | Cobenfy, Schizophrenia treatment, Trospium, Xanomeline
The Story of Tim: A Turning Point Tim, a young man in his mid-20s, had been struggling with schizophrenia for years. Despite multiple antipsychotic trials, his symptoms remained poorly controlled. He experienced severe side effects—weight gain, sedation, and...
